SynsoryBio

"If-then" conditional logic for protein drugs

Y CombinatorWinter 2024ActiveHealthcareTherapeuticsSynthetic BiologyBiotechTherapeuticsOncology

What they do

Problem

Highly potent protein drugs can cause systemic toxicity because they activate throughout the body instead of only at diseased tissue.

Solution

A conditional “if-then” protein therapeutic platform that senses tissue context in the body and activates drug function only at diseased sites.

Who it's for

Biopharma companies and drug developers developing protein therapeutics for diseases like cancer and autoimmune disorders.

Founders

Elliot Tague

Founder

I am a PhD and inventor in the fields of synthetic biology and protein engineering. I got my PhD from Boston University, spent time as a visiting graduate student in George Church's lab at Harvard, and worked in various biotech startups

Nathan Tague

Founder

I’m a co-founder of SynsoryBio, where we are creating therapeutics that sense-and-respond to disease. I have a background in synthetic biology and protein engineering with a PhD in Biomedical Engineering.